1. Treatment preference among people with cystic fibrosis: the importance of reducing treatment burden;Cameron;Chest,2022
2. The prevalence of children in the UK cystic fibrosis registry on long term anti-Pseudomonas aeruginosa (PA) inhaled antibiotics who become culture negative for PA and a survey of practice for discontinuing treatment;Gilchrist;J Cyst Fibros,2023
3. Impact of chronic medication de-escalation in patients with cystic fibrosis taking elexacaftor, tezacaftor, ivacaftor: a retrospective review;Guenther;J Cyst Fibros,2023
4. Use of cystic fibrosis inhaled medication before and after elexacaftor/tezacaftor/ivacaftor initiation;Manika;J Cyst Fibros,2023
5. Cystic Fibrosis Foundation Patient Registry 2022 Annual Data Report. Bethesda, Maryland, ©2023 Cystic Fibrosis Foundation.